VEGFA and melanoma: Currently, there are several clinical trials of anti‐PD‐1/L1‐based combination therapy for advanced melanoma including histone deacetylase inhibitor, tumor‐infiltrating lymphocytes therapy, vaccine therapy, vascular endothelial growth factor‐targeting therapies, preferentially expressed antigen in melanoma (PRAME)‐targeted bispecific proteins, T‐cell receptor‐T targeting PRAME, and more.